USPlabs destroys $8M worth of products; Novartis responds to FDA warning letter;

> Novartis ($NVS) said in its earnings release that it has responded to an FDA warning letter it received in May for a Sandoz plant in Unterach, Austria, and that it is working closely with the agency to resolve the issues. Release (PDF)

> Russia's Rafarma Pharmaceuticals and JSC F-Synthesis have a new exclusive agreement for the production of the anticancer drug Imatinib. Release

> Singapore has reported that exports of pharmaceuticals crashed 35.4% last month. Story

> Albemarle's fine chemical sales were undercut by falling volume and utilization in the last quarter. Report

And Finally... The FDA says that USPlabs voluntarily destroyed $8 million worth of OxyElite Pro and Jack3d because they contain DMAA, which the agency said can cause health problems. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.